307 related articles for article (PubMed ID: 34025681)
41. Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial.
Misawa S; Sato Y; Katayama K; Nagashima K; Aoyagi R; Sekiguchi Y; Sobue G; Koike H; Yabe I; Sasaki H; Watanabe O; Takashima H; Nishizawa M; Kawachi I; Kusunoki S; Mitsui Y; Kikuchi S; Nakashima I; Ikeda S; Kohara N; Kanda T; Kira J; Hanaoka H; Kuwabara S;
Lancet Neurol; 2016 Oct; 15(11):1129-37. PubMed ID: 27496680
[TBL] [Abstract][Full Text] [Related]
42. A review of POEMS syndrome.
Dispenzieri A; Buadi FK
Oncology (Williston Park); 2013 Dec; 27(12):1242-50. PubMed ID: 24624542
[TBL] [Abstract][Full Text] [Related]
43. [POEMS syndrome: monoclonal plasma cell disorder with polyneuropathy].
Kamezaki K; Nagafuji K
Nihon Rinsho; 2007 Dec; 65(12):2235-7. PubMed ID: 18069266
[TBL] [Abstract][Full Text] [Related]
44. Alterations in choroidal vascular structures due to serum levels of vascular endothelial growth factor in patients with POEMS syndrome.
Yokouchi H; Nagasato D; Mitamura Y; Egawa M; Tabuchi H; Misawa S; Kuwabara S; Baba T
Sci Rep; 2023 Jun; 13(1):10650. PubMed ID: 37391497
[TBL] [Abstract][Full Text] [Related]
45. Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis.
Scarlato M; Previtali SC; Carpo M; Pareyson D; Briani C; Del Bo R; Nobile-Orazio E; Quattrini A; Comi GP
Brain; 2005 Aug; 128(Pt 8):1911-20. PubMed ID: 15975949
[TBL] [Abstract][Full Text] [Related]
46. Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study.
Misawa S; Sato Y; Katayama K; Hanaoka H; Sawai S; Beppu M; Nomura F; Shibuya K; Sekiguchi Y; Iwai Y; Watanabe K; Amino H; Ohwada C; Takeuchi M; Sakaida E; Nakaseko C; Kuwabara S
BMJ Open; 2015 Nov; 5(11):e009157. PubMed ID: 26560063
[TBL] [Abstract][Full Text] [Related]
47. Changes in subfoveal choroidal thickness and reduction of serum levels of vascular endothelial growth factor in patients with POEMS syndrome.
Yokouchi H; Baba T; Misawa S; Kitahashi M; Oshitari T; Kuwabara S; Yamamoto S
Br J Ophthalmol; 2017 Jun; 101(6):786-790. PubMed ID: 27707692
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of novel agents in patients with nephropathy associated with POEMS syndrome.
Cheng S; Huang L; Fan W; Liang D; Zhu X; Jiang S; Ge Y
Int Urol Nephrol; 2022 Sep; 54(9):2317-2325. PubMed ID: 35133575
[TBL] [Abstract][Full Text] [Related]
49. Cereblon expression is a prognostic marker in newly diagnosed POEMS syndrome treated with lenalidomide plus dexamethasone.
Cai QQ; Gao XM; Le J; Zhao H; Cai H; Cao XX; Li J
Ann Hematol; 2021 Jun; 100(6):1547-1552. PubMed ID: 33839882
[TBL] [Abstract][Full Text] [Related]
50. [POEMS syndrome revealed by a scleroderma-like skin thickening].
Toussaint P; Sibaud V; Labbe L; Geniaux M
Ann Dermatol Venereol; 2000 Jan; 127(1):73-6. PubMed ID: 10717569
[TBL] [Abstract][Full Text] [Related]
51. Atypical polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes syndrome without polyneuropathy: A case report.
Li Q; Xu F; Duan JF; Tang YF
Medicine (Baltimore); 2020 Jul; 99(27):e20812. PubMed ID: 32629667
[TBL] [Abstract][Full Text] [Related]
52. POEMS syndrome: clinical update.
Brown R; Ginsberg L
J Neurol; 2019 Jan; 266(1):268-277. PubMed ID: 30498913
[TBL] [Abstract][Full Text] [Related]
53. Polyneuropathy, organomegaly, endocrinopathy, monoclonal band, and skin (POEMS) changes syndrome presenting with a pseudosensory level: a case report.
Paranavitane S; Gooneratne L; Chang T
J Med Case Rep; 2019 Dec; 13(1):384. PubMed ID: 31878962
[TBL] [Abstract][Full Text] [Related]
54. Endocrine Evaluation in POEMS Syndrome: A Cohort Study.
Yang H; Zhao H; Gao X; Huang X; Cao X; Zhou D; Xia W; Li J
Front Endocrinol (Lausanne); 2020; 11():536241. PubMed ID: 33193075
[TBL] [Abstract][Full Text] [Related]
55. [An unusual case of POEMS syndrome: in absence of clinical sign of polineuropathy.].
Vainieri AFM; Morelli S
Recenti Prog Med; 2019 Jun; 110(6):302-305. PubMed ID: 31282487
[TBL] [Abstract][Full Text] [Related]
56. [An illustrative case of the POEMS syndrome].
Radermecker A; Bonnet C; Lutteri L; Chapelle AC; Petignot S; Lievens I; Caers J
Rev Med Liege; 2021 Mar; 76(3):156-159. PubMed ID: 33682383
[TBL] [Abstract][Full Text] [Related]
57. POEMS syndrome: origination from clonal plasma cells or B cells?
Zhou L; Lu J; Lin Z; Wang X; Luo L; Wang C; Hong L; Xu R; Huang H
Hematology; 2023 Dec; 28(1):2186044. PubMed ID: 36897012
[TBL] [Abstract][Full Text] [Related]
58. Treatment response and prognosis of POEMS syndrome coexisting with Castleman disease.
Suichi T; Misawa S; Sekiguchi Y; Shibuya K; Tsuneyama A; Suzuki YI; Nakamura K; Kano H; Kuwabara S
J Neurol Sci; 2020 Jun; 413():116771. PubMed ID: 32172013
[TBL] [Abstract][Full Text] [Related]
59. POEMS Syndrome Showing Left Ventricular Dysfunction and Extracellular Edema Assessed by Cardiac Magnetic Resonance Imaging.
Takahashi Y; Iwano H; Nakano I; Fukushima A; Naya M; Shimizu A; Matsuno Y; Oyama-Manabe N; Anzai T
Intern Med; 2019 Sep; 58(17):2539-2543. PubMed ID: 31118405
[TBL] [Abstract][Full Text] [Related]
60. Polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome with dilated cardiomyopathy: A case report.
Li JR; Feng LY; Li JW; Liao Y; Liu FQ
World J Clin Cases; 2024 Jan; 12(3):601-606. PubMed ID: 38322456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
